From ClinicalTrials.gov
GLP-1 clinical trial results
290 Phase 3 trials with posted results, 146 of them named. Each page shows the results and side effects arm by arm, as the registry posts them. The newest update at source is Nov 4, 2026.
Largest first
Liraglutide trials with results
90 trials, 50,385 participants.
| Trial | Medication | People | Primary result |
|---|---|---|---|
| LEADERLiraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results | Liraglutide | 9,341 | Time From Randomisation to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) (percentage of subjects), from randomisation (visit 3; month 0) to last contact (visit 16; up to month 60+30 days). Liraglutide: 13.0; Placebo: 14.9. |
| GRADEA Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes | Liraglutide | 7,850 | Time to HbA1c>=7%, While Receiving Metformin and the Randomly Assigned Glucose-lowering Study Medication (years), Quarterly for 4 to 7 years. Glargine Insulin U-100: 1.3; Glimepiride: 1.3; Liraglutide: 1.5; Sitagliptin: 0.8. |
| NCT01272219Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes | Liraglutide | 3,731 | Change From Baseline in Fasting Body Weight (percent change), Week 0, Week 56. Liraglutide 3.0 mg (56-Week): -7.98; Liraglutide Placebo (56-Week): -2.62. |
| DUAL IDual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes | Liraglutide | 1,663 | Mean Change From Baseline in HbA1c (Glycosylated Haemoglobin) at Week 26. (Percentage of glycosylated haemoglobin), Week 0, week 26. IDeg: -1.44; IDegLira: -1.91; Liraglutide: -1.28. |
| ADJUNCT ONEThe Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes | Liraglutide | 1,398 | Change From Baseline in HbA1c (Glycosylated Haemoglobin) (percentage of glycosylated haemoglobin), Week 0, week 52. Liraglutide 0.6 mg: -0.45; Liraglutide 1.2 mg: -0.50; Liraglutide 1.8 mg: -0.54; Placebo: -0.34. |
| LEAD-2To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together | Liraglutide | 1,091 | Change in Glycosylated A1c (HbA1c) at Week 26 (Percentage point of total HbA1c), week 0, week 26. Lira 0.6 + Met: -0.69; Lira 1.2 + Met: -0.97; Lira 1.8 + Met: -1.00; Met Mono: 0.09; Met + Glim: -0.98. |
| DUAL VIIIA 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus | Liraglutide | 1,012 | See the trial's page: several measures or groups. |
| NCT00856986The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes | Liraglutide | 987 | Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 26. (Percentage point of total HbA1c), Week 0 (Randomisation), week 26. Lira 1.8: 0.02; Insulin Detemir + Lira 1.8: -0.51. |
| NCT00614120Effect of Liraglutide or Glimepiride Added to Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes | Liraglutide | 929 | Change in Glycosylated Haemoglobin A1c (HbA1c) (percentage point of total HbA1c), week 0, week 16. Lira 0.6 + Met: -1.0; Lira 1.2 + Met: -1.3; Lira 1.8 + Met: -1.4; Glim + Met: -1.3. |
| NCT01029886Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes | Liraglutide | 912 | Change in HbA1c From Baseline to Week 26 (percentage of total hemoglobin), Baseline, Week 26. Exenatide Once Weekly: -1.28; Liraglutide Once Daily: -1.48. |
| NCT01272232Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes | Liraglutide | 846 | Change (%) From Baseline in Body Weight (Fasting) (percent change), Week 0, week 56. Liraglutide 3.0 mg: -5.9; Liraglutide 1.8 mg: -4.6; Liraglutide Placebo: -2.0. |
| NCT01128894A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide. | Liraglutide | 841 | Mean Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 32 (Percentage of HbA1c in the blood), Baseline and Week 32. Albiglutide 50 mg: -0.78; Liraglutide 1.8 mg: -0.99. |
| ADJUNCT TWOThe Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes | Liraglutide | 835 | Change From Baseline in Glycosylated Haemoglobin (HbA1c) (Percent (%) glycosylated haemoglobin), Week 0, Week 26. Liraglutide 0.6 mg: -0.23; Liraglutide 1.2 mg: -0.23; Liraglutide 1.8 mg: -0.32; Liraglutide Placebo: 0.01. |
| DUAL I JapanA Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus. | Liraglutide | 819 | Change From Baseline in HbA1c (Glycosylated Haemoglobin) Tested for Non-inferiority of IDegLira vs IDeg and Superiority of IDegLira vs Lira (Percentage of HbA1c), Week 0, Week 52. Insulin Degludec/Liraglutide: -2.42; Insulin Degludec: -1.80; Liraglutide: -1.80. |
| LEAD-3To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c | Liraglutide | 746 | Change in Glycosylated Haemoglobin A1c (HbA1c) at Week 52 (percentage point of total HbA1c), week 0, week 52. Lira 1.8: -1.14; Lira 1.2: -0.84; Glimepiride: -0.51. |
| DUAL I ChinaA Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) | Liraglutide | 720 | Change in HbA1c (Percentage points of HbA1c), Week 0, week 26. Insulin Degludec/Liraglutide: -1.71; Insulin Degludec: -1.20; Liraglutide: -1.16. |
| PIONEER 4Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus | Liraglutide | 711 | See the trial's page: several measures or groups. |
| NCT00700817The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus | Liraglutide | 665 | Mean Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) at Week 26 (Percentage point of total HbA1c), Week 0, Week 26. Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg: -1.24; Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg: -1.5; Sita -> Sita: -0.9. |
| NCT01296412Comparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403) | Liraglutide | 653 | Change From Baseline in Hemoglobin A1c (A1C) (percent), Baseline and Week 26. Sitagliptin +/- Glimepiride: -1.32; Liraglutide: -1.42. |
| NCT02505334A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus. | Liraglutide | 635 | Change in Glycosylated Haemoglobin (HbA1c) (Week 26) (Percentage (%) of HbA1c), Week 0, Week 26. Liraglutide 1.8 mg: -0.23; Liraglutide 0.9 mg: 0.17. |
| DUAL VA Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus | Liraglutide | 557 | Change From Baseline in HbA1c (Glycosylated Haemoglobin) (Percentage (%)), Week 0, week 26. Insulin Degludec/Liraglutide (IDegLira): -1.81; Insulin Glargine (IGlar): -1.13. |
| LixiLan-GEfficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period | Liraglutide | 514 | Change From Baseline in Glycated Hemoglobin (HbA1c) to Week 26: Core Period (percentage of HbA1c), Baseline, Week 26. Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC): -1.02; GLP-1 Receptor Agonist: -0.38. |
| NCT02420262A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus | Liraglutide | 506 | Change in HbA1c (Glycosylated Haemoglobin) (Percentage of glycosylated haemoglobin), Week 0, Week 26. IDegLira: -1.48; IGlar + IAsp: -1.46. |
| NCT01733758A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM) | Liraglutide | 494 | Model-adjusted Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 (Percentage of HbA1c in the blood), Baseline and Week 24. Placebo: 0.25; Albiglutide 30 mg Weekly: -1.10; Albiglutide 50 mg Weekly: -1.30. |
| LEAD-6Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes | Liraglutide | 467 | Change in Glycosylated A1c (HbA1c) at Week 26 (percentage point of total HbA1c), week 0, week 26. Liraglutide -> Liraglutide -> Liraglutide: -1.12; Exenatide -> Liraglutide -> Liraglutide: -0.79. |
| DUAL II ChinaA Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD) | Liraglutide | 453 | Change in HbA1c (Percentage point of HbA1c), Week 0, week 26. Insulin Degludec/Liraglutide: -1.93; Insulin Degludec: -1.06. |
| NCT01617434The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes | Liraglutide | 451 | Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 26 (percentage of glycosylated haemoglobin), Week 0 to Week 26. Liraglutide: -1.30; Placebo: -0.11. |
| DUAL IIIThe Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy | Liraglutide | 438 | Change in Glycosylated Haemoglobin (HbA1c) From Baseline (Randomisation, Visit 2) (percentage of glycosylated haemoglobin), Week 0, week 26. Insulin Degludec/Liraglutide + Oral Anti Diabetic Drugs (OADs): -1.32; Liraglutide or Exenatide + OADs: -0.37. |
| DUALIVThe Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy | Liraglutide | 435 | Change in Glycosylated Haemoglobin (HbA1c) (percentage of glycosylated haemoglobin), Week 0, Week 26. IDegLira: -1.45; Placebo: -0.46. |
| NCT00781937Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance | Liraglutide | 422 | Mean Percentage Change in Fasting Body Weight From Baseline (percentage), Week 0, week 56. Lira 3.0 mg: -6.11; Placebo: -0.05. |
| DUAL VIA Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms | Liraglutide | 420 | Change From Baseline in HbA1c (percentage), Week 0, week 32. IDegLira (1WT): -2.01; IDegLira: -2.02. |
| DUALTM IXA Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus | Liraglutide | 420 | See the trial's page: several measures or groups. |
| DUAL IIA Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes | Liraglutide | 413 | Change From Baseline in HbA1c (Glycosylated Haemoglobin) (percentage of glycosylated haemoglobin), Week 0, week 26. IDegLira: -1.90; IDeg: -0.89. |
| BEGINComparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin | Liraglutide | 413 | Change From Baseline in HbA1c (%) (Glycosylated Haemoglobin) (percentage of glycosylated haemoglobin), week 0, week 26. IDeg: 0.10; IDeg + Liraglutide: -0.74; IDeg + IAsp OD: -0.39. |
| NCT00393718Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes | Liraglutide | 400 | Glycosylated Haemoglobin A1c (HbA1c) After 24 Weeks of Treatment (percentage of total haemoglobin), after 24 weeks of treatment. Liraglutide: 6.99; Glibenclamide: 7.50. |
| SCALE InsulinEffect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin | Liraglutide | 396 | See the trial's page: several measures or groups. |
| NCT01512108Safety and Efficacy of Liraglutide in Combination With an OAD in Subjects With Type 2 Diabetes Insufficiently Controlled on OAD Alone | Liraglutide | 363 | See the trial's page: several measures or groups. |
| NCT01557166Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea | Liraglutide | 359 | Change From Baseline in Apnoea-hypopnoea Index (AHI) (events/hour), Week 0, Week 32. Liraglutide 3.0 mg: -12.22; Placebo: -6.08. |
| NCT01664247The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification | Liraglutide | 346 | Change From Baseline in Glycosylated Haemoglobin (HbA1c) (%) (percentage of glycosylated haemoglobin), Week 0, week 26. IDeg: -0.99; Placebo: -0.07. |
| NCT03101930Cardiovascular Effects of GLP-1 Receptor Activation | Liraglutide | 329 | See the trial's page: several measures or groups. |
| NCT02443155A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function | Liraglutide | 308 | Area Under the Concentration-time Curve (AUC) 0-4h of Mixed Meal Tolerance Test (MMTT) Stimulated C-peptide at Week 54 Relative to Baseline (Ratio of AUC), 0 - 4 hours post-dose on week 0 and week 54. NNC0114-0006 + Liraglutide (Experimental): 0.934; NNC0114-0006 (Experimental): 0.783; Liraglutide (Experimental): 0.709; Placebo (Placebo): 0.660. |
| NCT02964247LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors. | Liraglutide | 303 | See the trial's page: several measures or groups. |
| FIGHTFunctional Impact of GLP-1 for Heart Failure Treatment (FIGHT) | Liraglutide | 300 | Global Ranking of Predefined Events (rank), Randomization to 180 days. Liraglutide: 145.5; Placebo: 155.7. |
| SCALE IBTEffect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting | Liraglutide | 282 | See the trial's page: several measures or groups. |
| NCT01620489Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment | Liraglutide | 279 | Estimated Mean From the Statistical Model and Standard Deviation From Observed Data For Change From Baseline to Week 26 in HbA1c (%) (Glycosylated Haemoglobin) (percentage (%)), Week 0, Week 26. Lira 1.8 mg: -1.05; Placebo: -0.38. |
| RISE AdultRISE Adult Medication Study | Liraglutide | 267 | Insulin Sensitivity, M/I (x 10-5 mmol/kg/min per pmol/L), 3-months after a medication washout. Metformin Alone: 3.53; Glargine Followed by Metformin: 3.38; Placebo: 3.63; Liraglutide + Metformin: 3.49. |
| NCT00395746Effect of Liraglutide in Combination With Sulfonylurea (SU) on Blood Glucose Control in Subjects With Type 2 Diabetes | Liraglutide | 264 | Glycosylated Haemoglobin A1c (HbA1c) After 24 Weeks of Treatment (percentage of total haemoglobin), after 24 weeks of treatment. 0.6 mg + SU: 7.02; 0.9 mg + SU: 6.75; SU Mono: 8.02. |
| NCT01572740Efficacy and Safety of Liraglutide in Combination With Insulin Therapy Compared to Insulin Alone in Japanese Subjects With Type 2 Diabetes | Liraglutide | 257 | Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 16 (percentage of glycosylated haemoglobin), Week 0, Week 16. Lira + Insulin: -1.73; Placebo + Insulin: -0.43. |
| NCT02918279Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity | Liraglutide | 251 | Change in BMI SDS (Week 0, Week 56) (SDS score), Week 0, week 56. Liraglutide 3.0 mg: -0.25; Placebo: -0.02. |
| PIONEER 9Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes | Liraglutide | 243 | See the trial's page: several measures or groups. |
| NCT03038620Impact of Liraglutide 3.0 on Body Fat Distribution | Liraglutide | 235 | Relative Percent Reduction in Visceral Adipose Tissue Mass Measured by MRI (percentage of reduction in VAT), Baseline, 40 weeks. Liraglutide 3.0 mg: 12.49; Placebo: 1.63. |
| DUAL II JapanA Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs | Liraglutide | 210 | Change in Glycosylated Haemoglobin (HbA1c) (Percentage of HbA1c), week 0, week 26. Insulin Degludec/Liraglutide: -1.95; Insulin Degludec: -0.65. |
| NCT03374956Individualized Obesity Pharmacotherapy | Liraglutide | 193 | Change in Total Body Weight (percent change), baseline to 12 weeks. Intervention Group: -7.7; Control Group: -6.5. |
| NCT01234649Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM) | Liraglutide | 153 | Insulin Secretion-Sensitivity Index (IS-SI) (index), 84 weeks of treatment. Metformin XR Plus Liraglutide: 418.4; Metformin XR Plus Placebo: 333. |
| NCT03737240IDegLira HIGH Trial | Liraglutide | 145 | Change in Hemoglobin A1c (HbA1c) (percentage of HbA1c), Baseline, Week 26. IDegLira: -3.18; Basal-Bolus Insulin: -3.00. |
| EllipseEfficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes | Liraglutide | 135 | Change in HbA1c (Glycosylated Haemoglobin) (Percentage of HbA1c), Week 0, week 26. Liraglutide 1.8 mg: -0.643; Placebo: 0.415. |
| NCT03048578Clinical Efficacy and Safety of Using 3.0mg Liraglutide to Treat Weight Regain After Roux-en-Y Gastric Bypass Surgery | Liraglutide | 132 | Percentage of Participants Losing at Least 5% Enrollment Body Weight Measured Using Cochran-Mantel-Haenszel (CMH) Test (percentage of participants), 12 Months. Saxenda: 76; Placebo: 17. |
| SAXAPCOSLiraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS | Liraglutide | 88 | Absolute Body Weight (BW) (kilogram), 32 weeks of treatment. Liraglutide Pen Injector (Saxenda): 104.7; Placebo Liraglutide Pen Injector: 117.9. |
| NCT01753362Liraglutide In Overweight Patients With Type 1 Diabetes | Liraglutide | 84 | See the trial's page: several measures or groups. |
| NCT02889510Study to Assess the Efficacy of Liraglutide in Patients With Type 2 Diabetes Mellitus | Liraglutide | 76 | Changes From Baseline on Measurements of Respiratory Function Defined by Forced Expiratory Volume in 1 Second (FEV1) (% (FEV1)), 7 weeks. Liraglutide: 4.1; Placebo: 4.3. |
| LIPTLIPT - Liraglutide in Polycystic Ovary Syndrome | Liraglutide | 72 | Change in Endogenous Thrombin Potential (ETP) (nMolar x minutes), at time 0 and 26 weeks. Liraglutide: -56.7; Placebo: -8.2. |
| NCT01722266Liraglutide in the Treatment of Type 1 Diabetes Mellitus | Liraglutide | 72 | Change in Mean Weekly Glucose Concentrations (mg/dl), 12 Weeks. Placebo: 1; Liraglutide 1.8mg: -10; Liraglutide 1.2mg: -10; Liraglutide 0.6 mg: -0.3. |
| NCT03151005The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS | Liraglutide | 70 | Assessment of Reproductive Functions (mIU/ml), 12 weeks. Metformin-GLP-1 Receptor Agonist: 5.52; Metformin-Oral Contraceptive(OC): 5.33. |
| 1966Liraglutide in Type 1 Diabetes | Liraglutide | 69 | See the trial's page: several measures or groups. |
| NCT01784965Liraglutide and a Calorie Restricted Diet Augments Weight Loss and Decreases Risk of Type 2 Diabetes and CVD. | Liraglutide | 69 | Change in Weight Reported at 14 Weeks (kg), Baseline and 14 weeks. Placebo: -3.3; Liraglutide: -6.8. |
| NCT02953665Safety and Efficacy of Liraglutide in Parkinson's Disease | Liraglutide | 63 | Change in Unified Parkinson's Disease Rating Scale (UPDRS Part III Motor Examination) During "OFF" Time From Baseline to the End of Double-Blind Maintenance Period (units on a scale), From Baseline (Week 0) to end of Maintenance Period (up to 54 weeks). Full Analysis Set (Liraglutide-treated Subjects): -2.3; Full Analysis Set (Placebo-treated Subjects): -5.0. |
| NCT03158805Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated) | Liraglutide | 60 | Percent Change in Body Weight (% change), 40 week. Active Drug: -3.3; Placebo: 0.2. |
| NCT03010683Effects of Agonists of Glucagon Like Peptide - 1 Receptors (GLP-1R) on Arterial Stiffness, Endothelial Glycocalyx and Coronary Flow Reserve in Patients With Coronary Artery Disease and Patients With Diabetes Mellitus | Liraglutide | 60 | See the trial's page: several measures or groups. |
| STARDUSTLiraglutide and Peripheral Artery Disease | Liraglutide | 60 | Peripheral Transcutaneous Oxygen Pressure (mmHg), 6 months. Liraglutide Group: 54.2; Control Group: 43.4. |
| NCT02527200Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome | Liraglutide | 56 | Change in Body Mass Index (BMI) Standard Deviation Score (SDS) From Baseline to 16 Weeks (SDS score), Week 0, Week 16. Part A: Liraglutide: -0.18; Part A: Placebo: -0.18; Part B: Liraglutide: -0.50; Part B: Placebo: -0.48; Part A+B: Liraglutide: -0.33; Part A+B: Placebo: -0.29. |
| NCT00620282The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus | Liraglutide | 49 | Change in Acetylcholine (ACh)-Mediated Forearm Blood Flow (FBF) (mL/100 mL/min), week 0, week 12. Lira 1.8: 4.244; Placebo: -3.187; Glimepiride: 2.164. |
| NCT03115424Effect of GLP-1 Receptor Agonism After Sleeve Gastrectomy | Liraglutide | 46 | See the trial's page: several measures or groups. |
| 1974Effects of Single Doses of Liraglutide and Dapagliflozin on Ketogenesis in Type 1 Diabetes | Liraglutide | 43 | Difference in Ketone Bodies Formation After Single Dose of Liraglutide and Dapagliflozin (mM), 8 hours. Liraglutide 1.8 mg: 0.08; Placebo: 0.25; Dapagliflozin: 0.21. |
| DALDaily Liraglutide for Nicotine Dependence | Liraglutide | 40 | Number of Participants With 7-day Point Prevalence Smoking Abstinence at 12 Weeks Post-Target Quit Date (Participants), Week 18. Smoking Cessation Counseling & Liraglutide: 2; Smoking Cessation Counseling & Placebo: 2. |
| NCT03260881Liraglutide Effects on Epicardial Fat Inflammatory Genes | Liraglutide | 38 | See the trial's page: several measures or groups. |
| BELIEVEBinge Eating Liraglutide Intervention | Liraglutide | 36 | Binge Episodes (objective binge episodes per week), baseline and 17 weeks (or last observation carried forward). Liraglutide: -3.97; Placebo: -2.50. |
| NCT04883346Liraglutide (Saxenda(R)) in Adolescents With Obesity After Sleeve Gastrectomy | Liraglutide | 34 | See the trial's page: several measures or groups. |
| NCT01832532A Pilot Study of the Effects on Sleep Disordered Breathing (SDB) When Using the Drug Liraglutide for 4 Weeks | Liraglutide | 34 | Change in Apnea Hypopnea Index (AHI) From Baseline (apnea / hypopnea events per hour sleep), Baseline and 4 weeks. Treatment Group- Liraglutide: 38.2; Control Group: 34. |
| LASARESafety, Tolerability and Pharmacokinetics of Intraarticular 4P004 Single Dose in Patient With KL 2-4 Osteoarthritic Knee | Liraglutide | 34 | See the trial's page: several measures or groups. |
| DUALA Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification | Liraglutide | 31 | Change From Baseline in HbA1c (Glycosylated Haemoglobin) (Percentage of glycosylated haemoglobin), Week 0, week 26. IDegLira: -0.43; IDegLira + IAsp: -0.14. |
| NCT02518945Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes | Liraglutide | 26 | Absolute Change After 12 Weeks From Baseline in Mean HbA1c With Addition of Dapagliflozin Compared to Placebo. (% HbA1c), 12 weeks. Placebo: 0; Active Drugs: -0.66. |
| NCT02960659Title: Therapeutic Targets in African-American Youth With Type 2 Diabetes | Liraglutide | 24 | Change in Absolute Gluconeogenesis From Baseline to 12 Weeks (mg/kg LBM/min), Baseline to 12 weeks. Metformin: 0.018; Metformin and Liraglutide: -0.050. |
| NCT04466566A Study to Evaluate the Effect of Genetic Variation on Beta-cell Function During Fasting and Hyperglycemia in Nondiabetics | Liraglutide | 21 | See the trial's page: several measures or groups. |
| NCT01847313The Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Diabetic Kidney Disease | Liraglutide | 20 | MCP-1:Creatinine Ratio in Urine (ng/mmol), Up to 26 weeks. Liraglutide: 27.9; Control: 24.3. |
| NCT01755416Liraglutide Versus Insulin Mono-therapy in the Closed Loop Setting | Liraglutide | 18 | Blood Glucose Measures in Subjects on Closed Loop With Insulin and Liraglutide, Compared to the Closed Loop With Insulin Alone (mg/dl), 0-1500 min. Closed Loop/Insulin: 159.7; Closed Loop/Insulin/Liraglutide: 144.6. |
| NCT01937598Antidiabetic Effects of Adding a DPP-4 Inhibitor to Pre-Existing Treatment With an Incretin Mimetic in Patients With T2D | Liraglutide | 16 | Incremental Area Under the Plasma Glucose (BG) Concentration-time Profile (AUC) ([mg*min/dL]), 0 to 300 min post mixed meal test. Sitagliptin: 5678; Placebo: 5557. |
| LIDO52 Week Trial of Liraglutide in Type 1 Diabetes | Liraglutide | 15 | Assessment of Changes in Glycemic Control by HbA1c. (percentage of HbA1c), Measure changes in HbA1c at 24 and 52 weeks from baseline. Liraglutide: 0.3; Placebo: 0.2. |
| NCT01856790Effect of Liraglutide on Automated Closed-loop Glucose Control in Type 1 Diabetes | Liraglutide | 15 | Peak Post-prandial Venous Glucose Levels (mg/dL), 48 hours. Closed Loop Insulin Delivery: 98; Closed Loop + Liraglutide: 76. |
| NCT02516657Liraglutide in Adolescents With Type 1 Diabetes | Liraglutide | 5 | See the trial's page: several measures or groups. |
| NCT01206101Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation | Liraglutide | 3 | See the trial's page: several measures or groups. |
Updated automatically
What just changed in the registry
- TrialNew Semaglutide study registered: A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity
- TrialSemaglutide study now completed (was unknown): The Effect of Different Diets on Arterial Stiffness in Obese Patients on Semaglutide
- TrialSemaglutide study now recruiting (was not yet recruiting): Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes
- TrialExenatide study now completed (was active, not recruiting): Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol
- TrialTirzepatide study now recruiting (was not yet recruiting): AI-Assisted Lifestyle Intervention Versus Tirzepatide for Obesity and Newly Diagnosed Type 2 Diabetes
- TrialTirzepatide study now recruiting (was not yet recruiting): A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes
- TrialNew Liraglutide study registered: The Effect of Liraglutide on Body Weight, Body Composition, Ectopic Lipid Accumulation and Insulin Sensitivity in Subjects With Overweight or Obesity Without Diabetes
- TrialNew MariTide study registered: Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA)
Written from each source's own record as it changes. Every change on GLPcompare
GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.